89bio Announces Closing of Enrollment in its Phase 1b/2a NASH Trial and Reports New Preclinical Data Confirming BIO89-100’s Mechanism of Action Via Potent FGF Receptor Agonism
13 avr. 2020 08h30 HE
|
89bio, Inc.
- Closed enrollment in its Phase 1b/2a NASH trial with 98% of patients enrolled and delays initiation of its SHTG trial due to the COVID-19 pandemic; Reaffirms guidance for NASH trial topline data in...
89bio Appoints Healthcare Industry Veteran Steven Altschuler, M.D., as Chairman of the Board of Directors
25 mars 2020 16h05 HE
|
89bio, Inc.
SAN FRANCISCO, March 25, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
18 mars 2020 16h05 HE
|
89bio, Inc.
- BIO89-100 Phase 1b/2a NASH study on track for topline data in 2H20 - - Initiation of Phase 2 SHTG study planned in 1H20 - SAN FRANCISCO, March 18, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq:...
89bio to Present at the SVB Leerink 9th Annual Global Healthcare Conference
21 févr. 2020 16h05 HE
|
89bio, Inc.
SAN FRANCISCO, Feb. 21, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
Novel Probiotic-Prebiotic supplement blend supports a healthy liver
23 janv. 2020 10h00 HE
|
Life Extension
Fort Lauderdale, Fla., Jan. 23, 2020 (GLOBE NEWSWIRE) -- Because liver health is vital at any age, Life Extension® has developed a novel approach to supporting a healthy liver. FLORASSIST® Liver...
PROVECTUS BIOPHARMACEUTICALS ANNOUNCES CHANGES TO BOARD OF DIRECTORS
24 avr. 2018 07h00 HE
|
Provectus Biopharmaceuticals Inc.
FOR IMMEDIATE RELEASE Ed Pershing, CPA elected new Board chair Jack Lacey, MD named new Board director; also appointed new strategic advisory board chair KNOXVILLE, TN, April 24, 2018 ...
SECOND STUDY OF EXPANDED ACCESS PATIENTS TREATED WITH PV-10 FOR IN-TRANSIT MELANOMA PUBLISHED IN JOURNAL OF SURGICAL ONCOLOGY
19 avr. 2018 06h00 HE
|
Provectus Biopharmaceuticals Inc.
FOR IMMEDIATE RELEASE KNOXVILLE, TN, April 19, 2018 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com) (“Provectus” or the “Company”), a...
Streetwise Reports Examines How One Analyst Says This Biotech Company Could Potentially 'Double'
15 nov. 2017 09h00 HE
|
Streetwise Reports Llc
SAN FRANCISCO, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Analyst Grant Zeng of Zacks Small Cap Research examines what transpired with this biopharmaceutical company during Q3/17. Included in this article...
Biopsy Devices Market size to exceed $3bn by 2024: Global Market Insights Inc.
29 août 2016 10h00 HE
|
Global Market Insights
Ocean View, Delaware, Aug. 29, 2016 (GLOBE NEWSWIRE) -- Biopsy Devices Market size is estimated to see USD 3.1 billion revenues by 2024; as reported by Global Market Insights, Inc. Growing...
Cempra to Present Anti-NASH Data for Solithromycin at The Liver Meeting(R) 2015
11 nov. 2015 07h30 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Nov. 11, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...